0DOL logo

Biofrontera LSE:0DOL Stock Report

Last Price

€1.17

Market Cap

€55.3m

7D

0%

1Y

n/a

Updated

24 Jul, 2023

Data

Company Financials

0DOL Stock Overview

A biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. More details

0DOL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Biofrontera AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Biofrontera
Historical stock prices
Current Share Price€1.17
52 Week High€1.22
52 Week Low€1.17
Beta0.82
1 Month Change0%
3 Month Change-3.92%
1 Year Changen/a
3 Year Change-59.96%
5 Year Change-80.12%
Change since IPO-57.38%

Recent News & Updates

Recent updates

Shareholder Returns

0DOLGB PharmaceuticalsGB Market
7D0%-1.7%-2.6%
1Yn/a-3.5%2.4%

Return vs Industry: Insufficient data to determine how 0DOL performed against the UK Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 0DOL performed against the UK Market.

Price Volatility

Is 0DOL's price volatile compared to industry and market?
0DOL volatility
0DOL Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.6%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0DOL has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0DOL's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997108n/awww.biofrontera.com

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; and Belixos, a medical skin care series for irritated and sensitive skin.

Biofrontera AG Fundamentals Summary

How do Biofrontera's earnings and revenue compare to its market cap?
0DOL fundamental statistics
Market cap€55.26m
Earnings (TTM)-€19.54m
Revenue (TTM)€24.97m

2.2x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0DOL income statement (TTM)
Revenue€24.97m
Cost of Revenue€4.90m
Gross Profit€20.08m
Other Expenses€39.62m
Earnings-€19.54m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 31, 2023

Earnings per share (EPS)-0.31
Gross Margin80.39%
Net Profit Margin-78.25%
Debt/Equity Ratio0%

How did 0DOL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/07/24 02:48
End of Day Share Price 2023/04/26 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biofrontera AG is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Navid MalikCavendish Historical (Cenkos Securities)
Robert WassermanDawson James Securities